Hypertension treatment in a medicare population: Adherence and systolic blood pressure control*

https://doi.org/10.1016/j.clinthera.2007.05.010Get rights and content

Abstract

Background:

Despite substantial trial evidence that demonstrates the effectiveness of pharmacologic treatment for reducing blood pressure (BP) and cardiovascular events, many patients are nonadherent to their hypertension treatment.

Objectives:

The purpose of this study was to examine patient adherence to hypertension medications using pharmacy data (ie, outpatient, inpatient, and mail-order prescriptions) and the association between adherence measures and systolic BP (SBP) control.

Methods:

The study included Medicare+Choice beneficiaries (aged ≥ 65 years) who were continuously enrolled in an integrated delivery system in 2003, and who had documented hypertension and received ≥1 hypertension drug in 2002. This analysis used automated clinical data and the 2000 US Census. We estimated 2 measures of hypertension treatment adherence in 2003 using the supply of dispensed drugs in days (proportion of days covered ≥80%): (1) adherence to ≥1 hypertension drug; and (2) adherence to the full hypertension treatment regimen. We defined the regimen by the number of hypertension drugs used concurrently in 2002. We assessed adherence annually and during the 30, 60, and 90 days before an SBP measurement. Logistic regression was used to examine the association between adherence and the number of drugs in the hypertension regimen, as well as the association between adherence and elevated SBP (≥140 mm Hg). We adjusted for patient sociodemographic and clinical characteristics.

Results:

The majority (52.8%) of patients had multidrug hypertension regimens. In 2003, 87.3% of subjects were adherent to ≥ 1 hypertension drug; 72.1% were adherent to their full regimen. After adjustment, we found that subjects with multidrug regimens were significantly more likely to be adherent to ≥ 1 drug and significantly less likely to be adherent to their full regimen, compared with patients on a 1-drug regimen. Over one-third of subjects had elevated SBP in 2003. Both adherence measures were associated with lower odds of having elevated SBP (eg, odds ratio = 0.87 [95% CI, 0.84–0.89] for adherence to the full regimen). For subjects with multidrug regimens, partial adherence and nonadherence to the regimen were associated with higher odds of having elevated SBP.

Conclusions:

Adherence measures using automated pharmacy data can identify patients who are nonadherent to their drug treatment regimen and who are more likely to have inadequately controlled BP. Adherence measures that account for the number of drugs in a patients' drug regimen might help identify additional patients at risk for poor BP outcomes due to partial treatment adherence.

References (39)

  • NealB. et al.

    Effects ofACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials

    Lancet

    (2000)
  • MoserM. et al.

    Clinical practice. Resistant or difficult-to-control hypertension

    N Engl J Med

    (2006)
  • SchroederK. et al.

    How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials

    Arch Intern Med

    (2004)
  • BramleyT.J. et al.

    Relationship of blood pressure control to adherence with anti hypertensive monotherapy in 13 managed care organizations

    J Manag Care Pharm

    (2006)
  • The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

    JAMA

    (2002)
  • ChooP.W. et al.

    Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to anti hypertensive therapy

    Med Care

    (1999)
  • ChapmanR.H. et al.

    Predictors of adherence with anti hypertensive and lipid-lowering therapy

    Arch Intern Med

    (2005)
  • PladevallM. et al.

    Clinical outcomes and adherence to medications measured by claims data in patients with diabetes

    Diabetes Care

    (2004)
  • Cited by (114)

    • Initial Combination Therapies

      2023, Hypertension: A Companion to Braunwald's Heart Disease
    • A systematic review of measures estimates adherence and persistence to multiple medications

      2019, Journal of Clinical Epidemiology
      Citation Excerpt :

      For example, Ferrario et al. [21], used a period of at least 60 days before discontinuation of index therapy to define a medication addition for a blood pressure-lowering medication in a class other than the index drug, whereas An and Nichol [17] defined addition as medications prescribed to treat the comorbid conditions other than the index condition during the 6-month period (index diabetes with comorbid hypertension or vice versa). Third, measuring adherence to “any medication”: Twelve studies assessed adherence from number of days with at least one medication available and defined patients as being adherent when they had collected at least 80% of one, that is, “any medication” [6,7,14,15,18,22–24,28,33,35,38]. Also the studies using this measure first assessed adherence for medication at class level and then calculated adherence to multiple medication classes at therapeutic level for glucose-lowering [6,7,14,18,33,38], blood pressure-lowering [15,18,22–24,28,35], or lipid-lowering medication [18,28].

    • Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience

      2018, Canadian Journal of Diabetes
      Citation Excerpt :

      Most patients who are hypertensive require at least 2 medications to achieve blood pressure (BP) targets, as demonstrated by large hypertension trials (4–10). Furthermore, adherence to treatment decreases significantly with the increasing number of pills patients require (11,12). This questions the traditional model of uptitration from monotherapy (13) and has spun interest in single-pill combinations.

    • Use of Combination Therapies

      2018, Hypertension: A Companion to Braunwald's Heart Disease
    View all citing articles on Scopus
    *

    The results from this study were presented in abstract form at the 11th Annual HMO Research Network Conference, April 4–6, 2005, Santa Fe, New Mexico, and at the Academy Health 2005 Annual Research Meeting, June 26–28, 2005, Boston, Massachusetts.

    View full text